In Brief: Selfcare, Inc.
This article was originally published in The Gray Sheet
Acquires diabetes care product supplier Can-Am Care for approximately $27 mil., including $13.6 mil. in cash, a $2 mil. note and about 1.1 mil. shares of Selfcare common stock. Can-Am, which markets insulin syringes, blood lancets, glucose tablets and specialty skin creams to pharmacies nationwide, generated approximately $25 mil. in revenues in fiscal 1997. Selfcare, which makes health maintenance and home self-test diagnostic products for the diabetes, women's health and nutritional supplement markets, calls the acquisition "an excellent fit with the rest of Selfcare's business" and anticipates "good opportunities to increase our total shelf space in pharmacies where our products are sold." The acquisition is expected to be accretive to earnings...
You may also be interested in...
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.